Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreHarness unparalleled healthcare data, advanced analytics, and cutting-edge technologies with our expertise to accelerate the development and commercialization of innovative medicines, enhancing patient lives.
Discover MoreBoost your innovation with IQVIA's expert team. Our comprehensive solutions integrate top-tier insights, technology, and expertise to maximize your asset's success in a competitive landscape.
Discover InnovationsNavigating MedTech's unique landscape: U.S. decision-making now rests with GPOs, IDNs, and payers, who demand solid value proof through rigorous outcomes analyses and pricing scrutiny.
Explore MedTechInvest in healthcare with confidence. Stay ahead of pharma and medical device trends using real-time, high-quality data. Access market insights, historical sales, prescription trends, and emerging product information for informed, risk-reduced decisions.
Access InsightsUnlock deeper health insights with unmatched data and innovative technology to enhance decision-making for your essential government programs.
Unlock InnovationsAccelerate digital innovation with our data-driven expertise in data science and healthcare, optimizing business processes for smarter decisions.
Navigate Health PlansLeverage digital innovation to cut costs, boost efficiency, and elevate patient engagement, all while enhancing quality and health outcomes.
Streamline DecisionsEnhance your ability to evaluate and forecast population risk swiftly and accurately by integrating unmatched data, expertise, and technology.
Uncover MoreTransform into a data-driven organization that enhances your specialty and showcases value to your members through digital transformation.
Explore NowA curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.
LEARN MOREExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTS"Discover the future through our enlightening podcasts available in the United States.
EXPLORE PODCASTSCOVID-19 is impacting all areas of our organizations, including marketing. It’s important to understand and prepare for major changes in the way we consume information in media today. After all, the reality is, we won’t go back to the way we used to conduct business.
Pre-COVID-19, we used multiple channels to engage and reach our intended audiences. But post-pandemic, we will rely more on those channels that traditionally haven’t been a priority or weren’t integrated into the overall mix. As we look to the future, we need to have an omnichannel mindset, and ask ourselves, “How do we utilize our channels in a fully integrated way to meet the new needs of our customer base, whether it’s HCPs or patients?”
When considering how we adjust our pre-COVID-19 marketing strategies to be relevant today, the most obvious place to start is in the digital arena. While digital channels have been increasing in priority for some time, the way interactions have recently adapted have catapulted digital to the front of the queue for consideration in any strategy.
Take HCPs as an example: 73 percent of doctors say that their interaction with digital has increased, while 46.5 percent of HCPs have increased their online research to replace information previously gained from reps1.
We foresee the world’s reliance on digital remaining just as strong in the future, while digital efforts will be much more extensive and integrated into our strategies.
In March 2020, streaming hours increased by 24 percent for connected television and 16 percent for streaming boxes vs 20192. OTT TV is a key area that we expect to evolve in line with digital. While traditional linear TV marketing (via regular broadcasts) will still have a place, we envision interaction with streaming and digital applications to continue growing at an unprecedented pace. Investment in linear TV has remained the same throughout the pandemic, but audience exposure has increased by 13percent3. In essence, this means you have more opportunity to engage, and refine the quality of that engagement, without having to increase investment.
Evolving from traditional TV into streaming and over-the-top services allows you to be much more granular with the audiences you want to communicate with, create content that people can immediately interact with, and develop the most relevant and impactful messages.
That’s where we can see a real difference in the approach to brand messaging before and after COVID-19. Before, brand teams would utilize typical messaging we’d expect to see. But now, there’s an opportunity to be more relevant in our call to actions relative to the situation we’re in now and beyond.
With this in mind, we recommend brand marketers continue to invest in TV, and explore the opportunities that digital and OTT will provide as we move into the second half of the year.
As both patients and HCPs continue to be more engaged and comfortable with digital channels, how people want to receive their information will evolve. Our challenge is to rethink how we deliver an integrated experience through a more effective mix of channels relevant to the new post-COVID-19 world, and with more relevant and targeted messages.
These are just some examples of the many omnichannel marketing opportunities we can take advantage of as our world evolves during and post-COVID-19. To discuss how you can adapt your strategy in more detail, reach an IQVIA omnichannel expert, or learn more about our omnichannel marketing services, go here.
1KLICK Health, Healthcasts HCP Survey
2Streaming on Connected TVs Up 24 Percent -Comscore Finds; Coronavirus Insights
3 iSpot COVID Pharma Report April 16 2020